2 months EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? Zacks
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
X